Candel Therapeutics Reports 30% Reduction in Prostate Cancer Recurrence Risk with CAN-2409 in Phase 3 Trial
核心洞察
Candel Therapeutics' CAN-2409 demonstrated a 30% reduction in prostate cancer recurrence risk in a completed pivotal phase 3 trial under FDA Special Protocol Assessment.
The company's viral immunotherapy platform includes CAN-3110 showing promising survival outcomes in recurrent glioblastoma with durable responses reported.
FDA has granted multiple designations including RMAT for prostate cancer and Fast Track status for several indications across both lead programs.
Candel Therapeutics has reported positive results from its phase 3 clinical trial of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer, demonstrating a 30% reduction in recurrence risk. The pivotal, placebo-controlled trial was conducted under a Special Protocol Assessment agreed with the U.S. Food and Drug Administration, positioning the company for potential regulatory submission.
Viral Immunotherapy Platform Shows Promise Across Multiple Cancers
The Massachusetts-based biotechnology company has developed two clinical-stage platforms based on genetically modified adenovirus and herpes simplex virus (HSV) constructs. These platforms are designed to deliver off-the-shelf therapies that can be administered broadly while harnessing the body's immune system to fight cancer.
CAN-2409, the lead candidate from the adenovirus platform, has completed its pivotal phase 3 trial in localized prostate cancer and has also been studied in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) with encouraging results. Subgroup analyses presented at the 2025 ASTRO Annual Meeting confirmed statistically significant improvements in disease-free survival with CAN-2409 across both conventional and hypofractionated radiation regimens.
Glioblastoma Program Demonstrates Durable Responses
Candel's second major program, CAN-3110 (linoserpaturev), derived from its HSV platform, is being evaluated in an ongoing phase 1b clinical trial for recurrent high-grade glioma. Early results have been encouraging, with median overall survival data showing promise and long-term survivors reported after repeated administrations. The program has generated scientific recognition, with findings published in leading journals such as Nature and Science Translational Medicine.
Regulatory Support Strengthens Development Path
The FDA has granted Fast Track Designation and Regenerative Medicine Advanced Therapy Designation to CAN-2409 for prostate cancer, Fast Track Designation in NSCLC, and both Fast Track and Orphan Drug Designation for PDAC. CAN-3110 has received both Fast Track and Orphan Drug Designation, underscoring its potential impact in a disease with limited treatment options.
Pipeline Advancement and Strategic Focus
The company is preparing to initiate a pivotal phase 3 trial in NSCLC in the second quarter of 2026 following a positive end-of-phase 2 meeting with the FDA. In pancreatic cancer, while the program has shown encouraging data, Candel has chosen to pause further development unless external funding is secured, focusing resources on prostate cancer and NSCLC.
CAN-3110 continues to generate survival data that supports the design of a randomized phase 2 trial in recurrent glioblastoma. Mature survival data from CAN-3110 in recurrent glioblastoma is anticipated in the fourth quarter of 2026.
Financial Position Supports Development Timeline
Candel reported a net loss of $11.3 million for the third quarter of 2025, compared to $10.6 million in the same quarter of 2024. Cash and cash equivalents stood at $87.0 million as of September 30, 2025, compared to $102.7 million at the end of 2024.
In October 2025, the company entered into a $130 million term loan facility with Trinity Capital Inc (搜索)., providing financial flexibility to advance its clinical programs. The facility includes multiple tranches tied to regulatory and clinical milestones, ensuring funding availability as the company progresses toward pivotal trials and potential regulatory submissions. With the addition of proceeds from the Trinity Capital loan facility, the company expects to fund operations into the first quarter of 2027.
Upcoming Milestones
Updated survival data from the NSCLC phase 2a trial is expected in the first quarter of 2026, followed by extended follow-up data from the prostate cancer phase 3 trial in the second quarter. The submission of a Biologics License Application (BLA) for CAN-2409 in prostate cancer is anticipated in the fourth quarter of 2026, alongside mature survival data from CAN-3110 in recurrent glioblastoma.